Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
February 16th, 2024
Here, we performed a systematic evaluation of patients diagnosed with gastric low-grade intraepithelial neoplasia by previous endoscopic biopsy and obtained a pathological diagnosis by complete resection of the lesion by endoscopic submucosal dissection (ESD), analyzing factors that potentially increase the risk of pathological escalation.
The scope of our research is the detection, diagnosis, and treatment of earlier gastrointestinal tumors. The question I would like to answer is how to predict the risk of pathological escalation of gastric low-grade intraepithelial neoplasia in order to get the diagnosis and best treatment of patients. Recent developments in digestive endoscopy involve minimally invasive techniques, improved imaging modalities, revision biopsies, and robot-assisted surgeries, which improve diagnosis and treatment outcomes.
In the future, we will focus our research scope on how to improve the diagnosis rate of early gastric cancer and includes the diagnostic of early gastric cancer through artificial intelligence as well as advanced endoscopic techniques. To begin, prepare the endoscope for surgical examination. Insert the endoscope through the patient's mouth and gradually advance it through the esophagus into the stomach.
Observe the interior of the digestive tract, examining the color, shape, texture, and distribution of blood vessels in the mucosa to identify possible lesions. Using ME-NBI technology, observe the microstructure of the gastric mucosal surfaces to determine the extent of lesions. After locating the lesion under white light endoscopy, zoom in from far to near the center of the lesion.
Examine the lesion to determine if the demarcation line exists and the extent of anisotropy of the microvascular and structural components. Next, use a disposable mucosal incision knife to make electrocoagulation marks all along the lesion boundary. Inject a prepared solution of saline, epinephrine, and indigo rouge into the submucosa with an endoscopic injection needle.
When the lesion has been completely elevated, make a circumferential incision around the lesion from the marking point. Then, dissect the lesion submucosally until it is completely removed. After dissection, carefully observe the wound.
Electrocoagulate the wound with electrocoagulation forceps. Use the snare to remove the tissue sample after complete excision. Pin the excised needle to a sample board before further tissue processing.
Overview
This study evaluates patients with gastric low-grade intraepithelial neoplasia diagnosed via endoscopic biopsy. It focuses on factors that may increase the risk of pathological escalation following complete resection using endoscopic submucosal dissection (ESD).
Key Study Components
Area of Science
- Gastroenterology
- Endoscopic techniques
- Pathology
Background
- Gastric low-grade intraepithelial neoplasia can progress to more severe conditions.
- Endoscopic submucosal dissection (ESD) is a minimally invasive technique for lesion removal.
- Understanding risk factors for pathological escalation is crucial for patient management.
- Recent advancements in endoscopy enhance diagnostic accuracy and treatment outcomes.
Purpose of Study
- To predict the risk of pathological escalation in gastric low-grade intraepithelial neoplasia.
- To improve diagnosis and treatment strategies for affected patients.
- To explore the role of advanced endoscopic techniques in early cancer detection.
Methods Used
- Endoscopic examination of the digestive tract to identify lesions.
- Use of ME-NBI technology for detailed observation of gastric mucosal surfaces.
- Electrocoagulation marking and submucosal dissection of identified lesions.
- Post-excision observation and tissue sample processing for pathological analysis.
Main Results
- Identification of key factors influencing pathological escalation risk.
- Successful application of ESD for complete lesion removal.
- Enhanced diagnostic capabilities through advanced imaging techniques.
- Potential for improved early detection of gastric cancer.
Conclusions
- Systematic evaluation of gastric low-grade intraepithelial neoplasia is essential.
- Advanced endoscopic techniques significantly improve patient outcomes.
- Future research should focus on integrating AI for better diagnostic accuracy.
Frequently Asked Questions
Executive Industry Relevance
Risk prediction for pathological escalation in gastric low-grade intraepithelial neoplasia (LGIN) is critical for early discovery-stage triage and portfolio prioritization in oncology R&D. Quantitative modeling of escalation risk enables more confident identification of patients at higher risk for progression, supporting targeted intervention strategies and resource allocation. Integrating predictive analytics into the discovery-to-preclinical continuum enhances translational continuity and reduces late-stage biological risk.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Supports identification of independent risk factors for disease progression using multivariate analysis.
- Enables mechanistic de-risking by clarifying which clinical and pathological features drive escalation.
- Improves predictive confidence for target validation in gastric neoplasia research.
Screening & Assay Development
- Facilitates development of quantitative risk models for patient stratification in clinical research.
- Standardizes assessment of lesion characteristics and pathological features for reproducible data collection.
- Enables scalable screening of patient cohorts based on validated risk factors.
Translational & Preclinical Research
- Aligns risk prediction outputs with translational biomarker strategies for early gastric cancer detection.
- Provides continuity from discovery of risk factors to preclinical validation of intervention strategies.
- Supports risk-adjusted advancement decisions for candidate biomarkers or therapeutic targets.
Pipeline & Workflow Integration
The risk prediction model integrates into the discovery-to-preclinical workflow by enabling early hypothesis testing, quantitative risk assessment, and prioritization of high-risk patient subsets for further study.
- Discovery Biology: Clarifies the contribution of age, lesion size, mucosal congestion, and surface ulceration to escalation risk.
- Screening: Provides reproducible, quantitative outputs for patient stratification and cohort selection.
- Analytics: Delivers logistic regression-based probability scores to compare risk across patient groups.
- Translational Research: Bridges discovery of risk factors with preclinical validation of diagnostic or therapeutic approaches.
- Enterprise Reuse: Establishes a reusable framework for risk modeling in other gastrointestinal neoplasia contexts.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in escalation risk assessment.
- Operational Value: Standardizes risk evaluation and supports reproducible, scalable patient screening.
- Strategic Value: Enables more informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of early detection or intervention programs.
Implementation Considerations
- Requires expertise in endoscopic imaging, pathology, and statistical modeling.
- Needs access to advanced endoscopic instrumentation and quantitative analytics infrastructure.
- Demands cross-team standardization of lesion assessment and data collection protocols.
- Adaptation may be needed for different patient populations or gastrointestinal neoplasia types.
- Model performance depends on quality and consistency of input clinical and pathological data.
